Compass Pathways

British biotechnology company developing psilocybin-based treatments for mental health disorders

CMPS Nasdaq ISIN US20451W1018 SEC CIK 1816590
Follow Compass Pathways Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$9.8M +92.9% vs same quarter last year
EPS, diluted −$0.31 +78.5% vs same quarter last year
Operating cash flow −$50.8M −44.6% vs same quarter last year
Operating income −$56.4M −39.2% vs same quarter last year
Net income by quarter
−$43.3M
−$17.9M
−$38.4M
−$137.7M
−$75.8M
−$253.8M
−$9.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$269.8M
FY24−$155.1M
FY23−$118.5M
FY22−$91.5M
FY21−$71.7M
FY20−$60.3M
FY19−$19.6M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$119.2M
FY23−$97.4M
FY22−$106M
FY21−$68.1M
FY20−$41.5M
FY19−$18M
FY18-